American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

members of the AJCC Precision Medicine Core

Research output: Contribution to journalComment/debate

60 Citations (Scopus)

Abstract

The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2-day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374.

Original languageEnglish (US)
Pages (from-to)370-374
Number of pages5
JournalCA Cancer Journal for Clinicians
Volume66
Issue number5
DOIs
StatePublished - Sep 1 2016

Fingerprint

Precision Medicine
Neoplasms
Checklist

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. / members of the AJCC Precision Medicine Core.

In: CA Cancer Journal for Clinicians, Vol. 66, No. 5, 01.09.2016, p. 370-374.

Research output: Contribution to journalComment/debate

@article{0404f6fdcaba42f0bf7a4257615a4553,
title = "American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine",
abstract = "The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2-day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374.",
author = "{members of the AJCC Precision Medicine Core} and Kattan, {Michael W.} and Hess, {Kenneth R.} and Amin, {Mahul B.} and Ying Lu and Moons, {Karl G.M.} and Gershenwald, {Jeffrey E.} and Gimotty, {Phyllis A.} and Mahul Amin and Susan Halabi and Lazar, {Alexander J.} and Mahar, {Alyson L.} and Tushar Patel and Sargent, {Daniel J.} and Weiser, {Martin R.} and Carolyn Compton",
year = "2016",
month = "9",
day = "1",
doi = "10.3322/caac.21339",
language = "English (US)",
volume = "66",
pages = "370--374",
journal = "Ca-A Cancer Journal for Clinicians",
issn = "0007-9235",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine

AU - members of the AJCC Precision Medicine Core

AU - Kattan, Michael W.

AU - Hess, Kenneth R.

AU - Amin, Mahul B.

AU - Lu, Ying

AU - Moons, Karl G.M.

AU - Gershenwald, Jeffrey E.

AU - Gimotty, Phyllis A.

AU - Amin, Mahul

AU - Halabi, Susan

AU - Lazar, Alexander J.

AU - Mahar, Alyson L.

AU - Patel, Tushar

AU - Sargent, Daniel J.

AU - Weiser, Martin R.

AU - Compton, Carolyn

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2-day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374.

AB - The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2-day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374.

UR - http://www.scopus.com/inward/record.url?scp=84955072254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955072254&partnerID=8YFLogxK

U2 - 10.3322/caac.21339

DO - 10.3322/caac.21339

M3 - Comment/debate

VL - 66

SP - 370

EP - 374

JO - Ca-A Cancer Journal for Clinicians

JF - Ca-A Cancer Journal for Clinicians

SN - 0007-9235

IS - 5

ER -